Filing Details

Accession Number:
0001179110-19-012292
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-03 18:11:11
Reporting Period:
2019-12-02
Accepted Time:
2019-12-03 18:11:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1229450 A Craig Wheeler C/O Momenta Pharmaceuticals, Inc.
301 Binney Street
Cambridge MA 02142
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-02 33,334 $15.37 46,011 No 4 M Direct
Common Stock Disposition 2019-12-02 33,334 $16.69 12,677 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2019-12-02 24,820 $0.00 24,820 $15.37
Common Stock Stock Option (Right to Buy) Disposition 2019-12-02 8,514 $0.00 8,514 $15.37
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2013-08-18 2020-02-18 No 4 M Direct
0 2014-02-18 2020-02-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 408,197 Indirect Craig Wheeler Revocable Trust
Common Stock 36,725 Indirect Craig A Wheeler 2016 Annuity Trust
Common Stock 60,000 Indirect Craig A Wheeler 2018 Annuity Trust
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018.
  2. This transaction was executed in multiple trades at prices ranging from $16.51 to $17.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.